Eugene Fine, M.D. presenting at the 2nd annual Ancestral Health Symposium (AHS12).
Abstract: We aim to discuss the rationale behind reducing insulin secretion via a carbohydrate restricted diet (CHORD) as a metabolic therapy in cancer, illustrated by data from our human pilot safety feasibility trial, as well as in vitro studies. Methods: Eligible outpatients had failed or refused > 2 standard chemotherapy courses and demonstrated FDG-positive PET scans. Conclusions: Preliminary study suggests safety and feasibility of CHORD in selected patients with advanced cancer. Disease stability correlated with metabolic ketosis and insulin inhibition, not caloric restriction. Results in this small sample size must be interpreted cautiously but support additional CHORD study for a complementary role with metabolic or cytotoxic therapies.
Full abstract and bio can be on our website: ancestralhealthsymposium2012.weebly.com/speakers.html